Brain tumor study reveals hidden toll of chemo on daily life
NCT ID NCT03257618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 26 adults with low-grade glioma who were receiving chemotherapy (temozolomide) for the first time after surgery. Researchers measured how the treatment affected patients' quality of life, thinking skills, and emotional well-being over one year. The goal was to better understand the full impact of the disease and its treatment, since preserving quality of life is a key priority when a cure is not available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LOW-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut regional du Cancer - Val d Aurelle
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Can a targeted pill slow brain tumor growth after surgery?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function